| Literature DB >> 27367679 |
Concepcion Parrado1, Marta Mascaraque2, Yolanda Gilaberte3, Angeles Juarranz4, Salvador Gonzalez5,6.
Abstract
Healthier life styles include increased outdoors time practicing sports and walking. This means increased exposure to the sun, leading to higher risk of sunburn, photoaging and skin cancer. In addition to topical barrier products, oral supplementations of various botanicals endowed with antioxidant activity are emerging as novel method of photoprotection. Polypodium leucotomos extract (PL, commercial name Fernblock(®), IFC Group, Spain) is a powerful antioxidant due to its high content of phenolic compounds. PL is administered orally, with proven safety, and it can also be used topically. Its mechanisms include inhibition of the generation and release of reactive oxygen species (ROS) by ultraviolet (UV) light. It also prevents UV- and ROS-induced DNA damage with inhibition of AP1 and NF-κB and protection of natural antioxidant enzyme systems. At the cellular level, PL decreases cellular apoptosis and necrosis mediated UV and inhibits abnormal extracellular matrix remodeling. PL reduces inflammation, prevents immunosuppression, activates tumor suppressor p53 and inhibits UV-induced cyclooxygenase-2 (COX-2) enzyme expression. In agreement with increased p53 activity, PL decreased UV radiation-induced cell proliferation. PL also prevents common deletions mitochondrial DNA damage induced by UVA, and MMP-1 expression induced Visible Light and Infrared Radiation. These cellular and molecular effects are reflected in inhibitions of carcinogenesis and photoaging.Entities:
Keywords: DNA; Polypodium leucotomos extract; antioxidant; immunosuppression; infrared (IR); oral; photoaging; photocarcinogenesis; photoprotection; ultraviolet (UV) radiation; visible light (VIS) radiation
Mesh:
Substances:
Year: 2016 PMID: 27367679 PMCID: PMC4964402 DOI: 10.3390/ijms17071026
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Polypodium leucotomos (PL) extract’s anti-UV effects: (A) decreases pro-inflammatory mechanisms of UV radiation include ROS-induced lipid peroxidation; (B) decreases UV-induced DNA damage; (C) increases the expression of active p53; (D) inhibits UV-induced Cox-2 enzyme levels; (E) reduces UV-induced nuclear transcription factors AP-1 and NF-κB; (F) reduces MMPs production; (G) decreases inflammation and vasodilation; and (H) inhibits skin immunodepression. Black arrows indicate increased/decreased effects due to UVR. ROS, reactive oxygen species; mtDNA, mitochondrial DNA; UV, ultraviolet; ECM, extracellular matrix; CPD, cyclobutane pyrimidine dimers; MMP, matrix metalloproteinase; MAPK, mitogen-activated protein kinases; AP-1, activator protein-1; NF-κB, nuclear factor kappa beta; TGF-β, transforming growth factor-β.; COX, cyclooxygenase enzymes; PGE2, prostaglandin E2; TNF-α, tumor necrosis factor-α; iNOS, isoforms of nitric oxide synthase; RANK, receptor activator of nuclear factor kappa-B; RANKL, receptor activator of nuclear factor kappa-B ligand.
Solar (ultraviolet (UV), infrared (IR), and visible light (VIS)) protection effects of Polypodium leucotomos (PL) and molecular target.
| UV Effects Tissue/Cellular/Molecular Target | PL Counteracts UV-Effects | References |
|---|---|---|
| DNA damage | Inhibit of DNA mutations | [ |
| Inhibit accumulation of CPD | [ | |
| Inhibit of 8-hydroxy-2′-deoxyguanosine | [ | |
| Inhibit of mtDNA mutations | [ | |
| Inflammation | Inhibit of TNF-α, iNOS, NF-κB, AP-1, COX-2 | [ |
| Decrease mast cell, neutrophils, and macrophage infiltration | [ | |
| Inhibit of PUVA induced vasodilation | [ | |
| Immunosuppression | Inhibit of UVR-mediated Langerhans cell depletion | [ |
| Protect DCs from UV-induced apoptosis | [ | |
| Induce DCs production of anti-inflammatory cytokines (IL-12) | [ | |
| Reduce of glutathione oxidation in blood and epidermis | [ | |
| Interfere the | [ | |
| Photo Carcinogenesis | Reduce the number of mice showing skin tumors at 8 weeks after the cessation of chronic UVB exposure | [ |
| Increase the number of p53(+) cells | [ | |
| Increase TIMP | [ | |
| Inhibit of angiogenesis | [ | |
| Inhibit of epidermal cell proliferation | [ | |
| Enhance the antioxidant plasma capacity | [ | |
| UV–ECM damage | Inhibit MMP-1 (also in melanoma cells) | [ |
| Increase TIMP (also in melanoma cells) | [ | |
| Increase the synthesis of types I, III, and V collagen | [ | |
| IR–VIS Effects Tissue/Cellular/Molecular Target | PL Counteracts IR–VIS Effects | [ |
| UV–ECM damage | Inhibit MMP-1 | [ |
mtDNA, mitochondrial DNA; ECM, extracellular matrix; CPD, cyclobutane pyrimidine dimers; TNF-α, tumor necrosis factor-α; iNOS, isoforms of nitric oxide synthase; NF-κB, nuclear factor kappa beta; AP-1, activator protein-1; COX-2, cyclooxygenase-2 enzyme; PUVA, Psoralens + UVA; DC, dendritic cells; UVR, ultraviolet Radiation; UCA, urocanic acid; MMP-1, matrix metalloproteinase-1; TIMP, tissue inhibitor of metalloproteinase.
Figure 2Tested anti IR–VIS effects of Polypodium leucotomos (PL) extract: (A) ultraviolet radiation (UV), visible light (VIS), and infrared radiation (IR) depth penetration in the skin; and (B) main PL effects reflect its capacity to decrease MMP-1 upregulation induced by cutaneous exposure to IR–VIS. Black arrows indicate increased/decreased effects due to IR–VIS.
Application of Polypodium leucotomos (PL) in the treatment of skin pathology.
| Pathology | Potential Clinical Use of PL | References |
|---|---|---|
| Melanoma | PL extract improves systemic photoprotection in patients at risk of MM | [ |
| The strongest effect of PL in patients with familial MM, those exhibiting a mutated CDKN2A and/or polymorphisms in MC1R | [ | |
| Idiopathic Photodermatosis | PL significant reduces skin reactions and subjective symptoms. | [ |
| Actinic Keratosis | PL improves PDT clearance and decreases AK recurrence rate at 6 months | [ |
| Pigmentary Disorders | Vitiligo | [ |
| Addition of PL to the treatment with NB-UVB shows an increased repigmentation mainly in the head and neck area | ||
| Melasma | [ | |
| PL had decreased Mean Melasma Area and Severity Index. Photographic assessment and patient self-assessments revealed mild and marked improvement by PL | ||
| Aging | PL decreased the proposed skin aging oxidative damage | See |
MM, melanoma; PDT, photodynamic therapy; AK, actinic keratosis; NB-UVB, narrow-band UVB.